

Total no. of samples	Galactomannan test result		KOH result	Culture
	Positive	Negative		
Serum (107)	21	86	-	-
Bronchial wash (74)	63	11	9	4
BAL (4)	4	-	3	2
Tracheal aspirate (3)	2	1	1	-

**P458**  
**Comparison of PCR protocols for detecting *Histoplasma capsulatum* and *Coccidioides* spp. DNA through a multi-center study**

Dunja Wilmes<sup>1,2</sup>, Ferry Hagen<sup>3,4,5</sup>, Cristina Verissimo<sup>6</sup>, Alexandre Alanio<sup>7,8</sup>, Volker Ricketts<sup>1,2</sup>, Maria José Buitrago<sup>9</sup>  
<sup>1</sup>FG16 Mycology, Robert Koch Institute, Berlin, Germany  
<sup>2</sup>Konsiliarlabor für Kryptokokkose und seltene Systemmykosen, Robert Koch Institute, Berlin, Germany  
<sup>3</sup>Westerdijk Fungal Biodiversity Institute (WI-KNAW), Utrecht, The Netherlands  
<sup>4</sup>Institute for Biodiversity and Ecosystem Dynamics, University of Amsterdam, Amsterdam, The Netherlands  
<sup>5</sup>Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, The Netherlands  
<sup>6</sup>Laboratório de Micologia Departamento de Doenças Infecciosas/Laboratório Nacional de Referência para Infecções Parasitárias e Fúngicas, Instituto nacional de saúde Doutor Ricardo Jorge, Lisbon, Portugal  
<sup>7</sup>Hôpital Saint-Louis, Paris, France  
<sup>8</sup>Institut Pasteur, National reference center for invasive mycoses and Antifungals, Paris, France  
<sup>9</sup>Mycology Reference Laboratory, National Center for Microbiology, Instituto de Salud Carlos III, Madrid, Spain

Poster session 3, September 23, 2022, 12:30 PM - 1:30 PM

Introduction: In-house real-time PCR (qPCR) is increasingly used for the diagnosis of endemic mycoses and diverse assays are in use in specialized laboratories. External quality control is currently lacking.

Objective: To compare the performance of different molecular detection protocols for the detection of *Histoplasma capsulatum* and *Coccidioides* spp. in a multicenter study involving five European laboratories.

Methods: Two test sample panels were sent to each laboratory which performed the analysis with their in-house assays. Recipients were blinded to sample content. The *Histoplasma*-panel included 14 samples representing a range of concentrations of *Histoplasma* DNA ( $n = 7$ ), as well as a negative control and DNA from other fungi to test for specificity (*Paracoccidioides lutzii*  $n = 1$ ; *Blastomyces dermatitidis*  $n = 1$ ; *Aspergillus fumigatus*  $n = 1$ ; *Emergomyces* spp.  $n = 2$ , and *Candida albicans*  $n = 1$ ). The *Coccidioides*-panel included 10 samples representing a range of DNA concentrations of *Coccidioides posadasii* ( $n = 6$ ), as well as a negative control and DNA from other fungi to test specificity (*Uncinocarpus reesii*  $n = 1$ ; *Trichophyton violaceum*  $n = 1$ ; and *Candida albicans*  $n = 1$ ). Regarding techniques used, four laboratories used *Histoplasma* qPCRs, and one laboratory a conventional PCR and a broad-range PCR (brPCR) for fungal DNA. Four laboratories used different *Coccidioides* qPCRs and one laboratory a brPCR to detect *Coccidioides* DNA.

Results: Concerning the *Histoplasma* panel, qPCR assays were the most sensitive and agreement in the lowest detected amount of *Histoplasma* DNA was very suitable, ranging from 1 pg to 4 pg [ $< 1$  genomic equivalent (mean sensitivity: 96.4%)]. The lowest detected amount of *Histoplasma* DNA by cPCR (sensitivity 71.4%) and the brPCR (sensitivity 42.9%) was 0.1 and 10 pg, respectively. Overall, sensitivity ranged from 42.9-100% (mean 83.3%). Overall specificity ranged from 78.6%-100%, with false positive results occurring with high DNA concentrations (200 pg/ $\mu$ l) of *Blastomyces* spp. in two laboratories that used qPCR, *Emergomyces* spp. by qPCR in one laboratory and *Aspergillus* in one laboratory that used cPCR. Concerning the *Coccidioides*

panel, sensitivity ranged from 33.3-100% (mean 76.6%), and agreement of the lowest detected amount of *Coccidioides* DNA by qPCR ranged from 1-16 pg ( $< 1$  genomic equivalent) (mean sensitivity: 87.5%) and in the brPCR 10 pg (sensitivity 33.3%). Specificity was between 87.5%-100%, with one false positive result occurring with high DNA concentrations (20 pg/ $\mu$ l) of *Uncinocarpus* in one laboratory using qPCR.

Conclusion: Specific protocols based on qPCR showed better sensitivity than conventional and brPCR. These methods are useful for the rapid and sensitive detection *Histoplasma* and *Coccidioides*. Application of these tests on clinical samples may speed up diagnosis and potentially limit laboratory exposure to these fungi. Comparisons of in-house tests are essential to assess the performance and detect potential cross-reactivities and achieve a consensus.

**P459**  
**The *Aspergillus* lateral flow assay for the diagnosis of chronic pulmonary aspergillosis**

Jie Peng<sup>1,2</sup>, Jun Yan<sup>1,2</sup>, Yuan Zhang<sup>1,2</sup>, Wang Yao<sup>1,2</sup>, He Wang<sup>1,2</sup>, Yan Su<sup>1,2</sup>, Zeqi Zhou<sup>1,2</sup>  
<sup>1</sup>Dynamiker Sub-Center of Beijing Key Laboratory for Mechanisms Research and Precision Diagnosis of Invasive Fungal Disease-Tianjin (China), Tianjin, China  
<sup>2</sup>Tianjin Enterprise Key Laboratory For Precision Diagnosis Technology of Invasive Fungal Diseases-Tianjin (China), Tianjin, China


Poster session 3, September 23, 2022, 12:30 PM - 1:30 PM

Objectives: Chronic pulmonary aspergillosis (CPA) is an uncommon and problematic pulmonary disease, complicating many other respiratory disorders. Measurement of *Aspergillus*-specific IgG antibodies had a higher sensitivity than either IgM, IgA, or IgE and it should therefore be considered the most appropriate test for screening CPA. *Aspergillus*-specific IgG antibody levels have been successfully used to monitor the response of CPA to medical therapy. Recently, a novel rapid test for *Aspergillus*-specific IgG antibody from Dynamiker Biotechnology (Tianjin) Co., Ltd. was released as a screening test of CPA. It is a fluorescent immunochromatographic cassette test using a monoclonal antibody against *Aspergillus*-specific IgG antibody and Europium nanoparticles (Eu NP) (Fig. 1). It is a semi-quantitative test which was easy to operate, rapid with portable detection devices, and can be widely accepted by clinical and primary medical (Fig. 2). We collect clinical samples to verify the detection performance of the Dynamiker Quic<sup>TM</sup> *Aspergillus*-specific IgG antibody (LFA) test.

Methods: In total, 102 patients were included and 42 patients were diagnosed with CPA. The pathogen was identified from sputum, BALF culture, lung resection surgery, bronchoscopy biopsy, percutaneous lung biopsy and BALF GM assay.

Results: The sensitivity, specificity, PLR, NLR and Kappa index of the IgG antibody test were 85.6%, 94.4%, 14.0%, 0.23% and 0.72, respectively.

Conclusions: The current work indicates that the Dynamiker Quic<sup>TM</sup> *Aspergillus* specific IgG antibody (LFA) test shows a promising application in the diagnosis of CPA. The results are accurate and reliable, and it could be used as an aid for the early rapid screening test of CPA.



**Figure 1. Diagram of the Dynamiker *Aspergillus* specific IgG antibody (LFA)**